Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

Pulmonary hypertension was previously considered a rare untreatable condition. The past
two decades have seen major changes in our understanding of the spectrum of disease …

Therapeutic options for pulmonary arterial hypertension (PAH) have increased over the last
decades. The advent of pharmacological therapies targeting the prostacyclin, endothelin, …

Background Uncontrolled studies suggested that aerosolized iloprost, a stable analogue of
prostacyclin, causes selective pulmonary vasodilatation and improves hemodynamics and …

Rationale: Pulmonary arterial hypertension in association with connective tissue disease (CTD-PAH)
has historically had a poor prognosis, with a 1-year survival rate among patients …

Rationale: Incident pulmonary arterial hypertension was underrepresented in most pulmonary
hypertension registries and may have a different disease profile to prevalent disease. …

Pulmonary hypertension (PH) is a heterogeneous condition. To date, no registry data exists
reflecting the spectrum of disease across the five diagnostic groups encountered in a …

Rationale: The management of chronic thromboembolic pulmonary hypertension (CTEPH)
has changed over recent years with the growth of pulmonary endarterectomy surgery and the …

Guidelines summarize and evaluate available evidence, with the aim of assisting health
professionals in proposing the best management strategies for an individual patient with a given …

… Dr Kiely has received speaker fees, honoraria and has been on advisory boards for Actelion,
Bayer, GSK, Pfizer and United Therapeutics and has received research grants from Actelion…